Abstract
The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Anti-Infective Agents
Title:The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery
Volume: 11 Issue: 2
Author(s): Hsiang-Kuang Tseng, Sheng-He Huang, Gregory Shackleford and Ambrose Jong
Affiliation:
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Abstract: The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Export Options
About this article
Cite this article as:
Tseng Hsiang-Kuang, Huang Sheng-He, Shackleford Gregory and Jong Ambrose, The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020005
DOI https://dx.doi.org/10.2174/2211352511311020005 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Reverse Phase Ultra-fast Liquid Chromatography Using Ion-pairing Reagent for Quantitative Assessment of Ceftriaxone in Rat Serum and Cerebrospinal Fluid
Current Pharmaceutical Analysis Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Fluoroquinolones: Blessings Or Curses
Current Drug Targets Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Transient Blood Brain Barrier Disruption Induced by Oleic Acid is Mediated by Nitric Oxide
Current Neurovascular Research Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Gene Therapy for Pituitary Tumors
Current Gene Therapy Docking Studies for Multi-Target Drugs
Current Drug Targets Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Fluoroquinolones in Pediatrics
Current Drug Therapy Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Symmetry Plane Detection in Brain Image Analysis: A Survey
Current Medical Imaging Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry MRI in Normal Myelination: A Pictorial Review
Current Pediatric Reviews